- Evaxion Biotech A/S EVAX and Pantherna Therapeutics GmbH announced a preclinical proof of concept for combining the two companies key technologies.
- The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model when delivered using Pantherna’s proprietary lipid nanoparticle mRNA platform.
- In continuation of these positive findings, Evaxion and Pantherna will further explore optimal LNP formulations to effectively deliver mRNA and DNA-encoded antigens identified by Evaxion’s AI platforms.
- In November, Evaxion Biotech announced interim safety and immunogenicity data from the Phase 1/2a study of its DNA-based cancer immunotherapy, EVX-02.
- EVX-02 is given with a checkpoint inhibitor and targets cancer mutations and neoantigens in patients with resected melanoma.
- In December, Evaxion signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB for the joint development of a novel cytomegalovirus (CMV) vaccine candidate.
- Evaxion will use its proprietary AI platform, RAVEN, to design a next-generation vaccine candidate that elicits cellular and humoral/antibody responses.
- EVAX stock was up by 12% at one point in the trading session.
- Price Action: EVAX shares are up 1.69% at $1.81 on the last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
